LRG GIST Patient Registry

NCT07697248 | Recruiting

• 1 other identifier: LRG2013PR112
• Study Type: observational
• Target: 5,000
• Locations: 1 country
• Sites: 1

Brief Summary

The Life Raft Group (LRG) Patient Registry is a structured database that collects comprehensive information about individuals diagnosed with GIST. The purpose of this registry is to facilitate research, improve understanding of the disease, track patient outcomes, and ultimately enhance patient care.

Conditions

GIST; GIST - Gastrointestinal Stromal Tumor; Gastrointestinal Stromal Tumor (GIST)

Keywords

GIST

Outcome Measures

Primary Outcomes (5)

• Overall survival

  Time from registry enrollment until death from any cause.

  From the date of registry enrollment until death from any cause, assessed through follow-up for up to 25 years.

• Progression Free Survival

  Time from registry enrollment until documented disease progression or death, whichever occurs first.

  From the date of registry enrollment until the first documented disease progression or death from any cause, whichever occurs first, assessed through follow-up for up to 25 years.

• Recurrence Free Survival

  Time from registry enrollment (or from complete surgical resection, if that is the clinically relevant starting point) until the first documented recurrence of GIST or death from any cause, whichever occurs first.

  From the date of complete surgical resection until the first documented recurrence of GIST or death from any cause, whichever occurs first, assessed through follow-up for up to 25 years.

• Disease Free Survival

  Disease-free survival is defined as the time from complete surgical resection of localized GIST until the first documented recurrence of GIST or death from any cause, whichever occurs first.

  From the date of complete surgical resection until the first documented recurrence of GIST or death from any cause, whichever occurs first, assessed through follow-up for up to 25 years.

• Time of Medication

  Duration of treatment with a specific systemic therapy (e.g., imatinib, sunitinib, regorafenib, ripretinib), measured from treatment initiation until permanent discontinuation for any reason, including disease progression, toxicity, patient preference, or death.

  From the date of treatment initiation until permanent discontinuation of the medication for any reason, assessed through follow-up for up to 25 years.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Gastrointestinal Stromal Tumor diagnosis

You may qualify if:

• Gastrointestinal Stromal Tumor diagnosis
• Provide written and informed consent

Sponsors & Collaborators

• The Life Raft Group: lead

Study Sites (1)

The Life Raft Group

Wayne, New Jersey, 07470, United States

RECRUITING

MeSH Terms

Conditions

Gastrointestinal Stromal Tumors

Condition Hierarchy (Ancestors)

Neoplasms, Connective Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases

Central Study Contacts

Patient Registry Department

CONTACT

973-837-9092; patientregistrydepartment@liferaftgroup.org

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 25 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 1, 2026
• First Posted: July 13, 2026
• Study Start: April 1, 2013
• Primary Completion (Estimated): December 31, 2099
• Study Completion (Estimated): December 31, 2099
• Last Updated: July 13, 2026

Record last verified: 2026-07

Locations

US (1)